Navigation Links
Tezampanel, TorreyPines Therapeutics' Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
Date:10/17/2007

Data Suggest Potential for Treating Motor System Disorders

LA JOLLA, Calif., Oct. 17 /PRNewswire/-- Tezampanel, a novel small molecule currently in clinical development by TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) for the treatment of acute migraine headache, was shown in an independent study to be effective in reversing or preventing muscle spasticity and rigidity in a rat model of spinal ischemia. These symptoms are commonly seen in Parkinson's disease, multiple sclerosis, cerebral palsy and other progressive motor system disorders caused by brain trauma or spinal cord injury.

In a study published in the October 17 issue of the Journal of Neuroscience, a team of international researchers found that tezampanel, identified in the study as NGX424, reduced muscle spasticity (stimulus-dependent increase in muscle tone) and rigidity (continuous stimulus-independent increase in muscle tone) in the hind legs of spinal ischemia-induced paraplegic rats. In humans with motor system disorders, muscle spasticity and rigidity, often combined with painful perception, can interfere with rehabilitation and daily activities.

The study was led by Michael P. Hefferan, Ph.D., and Martin Marsala, M.D., Anesthesiology Research Laboratory, Department of Anesthesiology, University of California, San Diego (UCSD). Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics, served as one of the study authors.

An AMPA/kainate receptor antagonist, tezampanel acts on glutamate receptors located in the brain and spinal cord. While essential to central nervous system function, excess glutamate production -- prompted by disease or injury -- can have pathological effects. In the study, tezam
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, ... OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE ... JURISDICTION AbbVie (NYSE: ABBV ) today announced financial ... "This was another very strong quarter for AbbVie, ... original guidance and announced plans to merge with Shire, a ...
(Date:7/24/2014)... OVERLAND PARK, Kan. , July 24, 2014 ... licensing of two compounds that will be added ... agreement with Australian-based CIMTECH Pty Ltd, a biotechnology ... and PAR 122 have shown promise in bone ... a license to develop the compounds for the ...
(Date:7/24/2014)... , and MARSEILLE, France , July ... Exclusive global license from University of Tokyo enables development ... (NGS) gene panels, for blood cancers  Mutations ... indicate favorable prognosis for patients with bone marrow disorders ... for developing companion diagnostics to guide treatment with new ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
... 9 Pharmacyclics, Inc.,(Nasdaq: PCYC ) today ... orally available, selective inhibitor of Bruton,s tyrosine,kinase, or ... model,for rheumatoid arthritis (RA). The data were presented ... being held this,week in Boston, MA., Researchers ...
... shows, investigational regimen resulted in 82 percent overall survival and 78 ... ... is presently being conducted in this ... patient population, LUGANO, Switzerland, June 9 In an ...
Cached Medicine Technology:Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 2Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 3Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 4Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma 2Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma 3Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma 4
(Date:7/25/2014)... (HealthDay News) -- The human brain can preserve oxygen ... new study finds. Although dehydration significantly reduces ... found that the brain compensates by increasing the amount ... research has helped us understand a lot more about ... extreme conditions," study first author Steven Trangmar, a researcher ...
(Date:7/25/2014)... Ticket Down is a reliable source for ... at California Memorial Stadium. With the post-World Cup emotions ... organizers of the 2014 Guinness International Champions Cup have brought ... With teams representing La Liga, English Premier League, Serie A, ... best football players from around the world to 12 American ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 This ... current state of the Galactooligosaccharides (GOS) industry ... basic overview of the industry, including definitions, applications ... Chinese domestic market analysis are provided with a ... of the market. A comparison between the international ...
(Date:7/25/2014)... News) -- Babies seem to learn even before they,re ... women are 34 weeks pregnant, their unborn babies can ... a familiar nursery rhyme, the researchers report. "The ... in the developing fetus," Charlene Krueger, nursing researcher and ... Nursing, said in a university news release. "This research ...
(Date:7/25/2014)... Newyorktermlifeinsurance.org has released a new blog post ... policies. , The newly released blog post aims ... exam life insurance plans and traditional policies. The article ... to provide a simple guide for purchasing life coverage. ... be purchased online. Although traditional plans do not have ...
Breaking Medicine News(10 mins):Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 2Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 3Health News:Rhymes Reveal Evidence of Learning in the Womb 2Health News:No Medical Exam Life Insurance and Traditional Plans - Newyorktermlifeinsurance.org Provides Quotes for All Types of Life Insurance 2
... Work and economy related stress is taking its toll on ... by American Laser Centers, the largest provider of non-invasive aesthetic services ... part in the survey (47 percent) currently feel some stress, while ... , The physical toll of their stress is also ...
... , SPRINGFIELD, Ohio, Aug. 14 AdCare Health Systems, ... term care, home care and management company, today reported financial results ... Revenues for the quarter ended June 30, 2009 were $6,613,127 as ... of $596,591. The increase was mostly due to improved occupancy in ...
... avoid becoming overweight, researchers say , FRIDAY, Aug. 14 ... obesity epidemic by forbidding their kids to eat certain foods ... may actually be making the situation worse, researchers say. ... food choices that will allow them to maintain a healthy ...
... , , SALT LAKE CITY, ... and respected brands in the nutritional supplement industry, having provided consumers ... years, is excited to announce the seven lucky winners of the ... Each grand prize winner won a 10-day vacation for two ...
... , , RICHMOND, ... TSPT ), a specialty pharmaceutical company focused on the development ... in neuroscience, today announced financial results for the three and ... Glenn A. Oclassen, President and Chief Executive Officer commented, ...
... , , , ... OXBO) today announced that the company has received approval to begin ... of Oxycyte(R) in traumatic brain injury (TBI). Oxycyte is the Company,s ... approval from Swissmedic means that we can begin enrolling patients," said ...
Cached Medicine News:Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 2Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 3Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 4Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 5Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 6Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 7Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 8Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 9Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 10Health News:Restrictive Diet for Kids May Backfire 2Health News:Schiff Awards Seven Lucky Winners the 'Trip of a Lifetime' 2Health News:Schiff Awards Seven Lucky Winners the 'Trip of a Lifetime' 3Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 2Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 3Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 4Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 5Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 6Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 7Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 8Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 9Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 10Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 11Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 12Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 13Health News:Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland 2Health News:Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland 3
The precise, fully reusable R-100 Pullback Device is an invaluable tool during plaque volumetric analysis....
... you perform exams from cardiac to angio. ... no compromises. An ideal 31 centimeters square, ... of cardiovascular and interventional imaging. With a ... variety of vascular and interventional procedures. The ...
... The RX daytona is a fully ... field in bench top analysers offering many ... standing systems. With reusable glass cuvettes, on ... and reagents, the random access analyser can ...
Inquire...
Medicine Products: